CD8+ TEMRA cells: A double-edged sword in immunity and disease—Mechanisms and therapeutic targets

The generation of long-lived immune memory is a hallmark of adaptive immunity, ensuring rapid recall responses upon antigen re-exposure. Within the memory CD8 + T cell compartment, T EMRA cells (CD45RA + CCR7 − ) represent a unique, terminally differentiated population defined by potent cytotoxicity and distinct migratory properties. Historically viewed as a state of replicative senescence and dysfunction, recent evidence has shifted this paradigm, portraying T EMRA cells as hyper-functional effectors with a Senescence-Associated Secretory Phenotype (SASP). This review comprehensively synthesizes the biological complexity of CD8 + T EMRA cells, dissecting the transcriptional (e.g., ZEB2, T-bet) and metabolic reprogramming (e.g., glycolytic reliance) that governs their fate. We critically examine their dichotomous roles in health and disease: while serving as indispensable sentinels in antiviral and anti-tumor immunity, their dysregulation contributes to tissue pathology in autoimmune disorders and chronic infections. Furthermore, we address the “tumor immunity paradox” by discussing the confounding role of bystander virus-specific cells and the predictive value of specific subsets (e.g., CX3CR1 + T EMRA ). Finally, we highlight the potential of targeting metabolic checkpoints and senescence pathways as novel therapeutic strategies to modulate T EMRA function in clinical settings. • CD8 + T EMRA cells are hyper-functional sentinels, distinct from exhaustion. • Metabolic reprogramming (e.g., PKM2, Glutamine) governs T EMRA cell fate. • CX3CR1 + T EMRA subset predicts favorable responses to cancer immunotherapy. • Bystander virus-specific T EMRA cells confound anti-tumor immune outcomes.